Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 6
1988 1
1989 3
1990 4
1991 6
1992 8
1993 6
1994 13
1995 20
1996 26
1997 18
1998 32
1999 25
2000 13
2001 20
2002 19
2003 27
2004 21
2005 24
2006 22
2007 15
2008 14
2009 11
2010 15
2011 17
2012 13
2013 14
2014 9
2015 16
2016 13
2017 14
2018 11
2019 11
2020 21
2021 17
2022 13
2023 11
2024 15
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

523 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Cornely OA, et al. N Engl J Med. 2007 Jan 25;356(4):348-59. doi: 10.1056/NEJMoa061094. N Engl J Med. 2007. PMID: 17251531 Free article. Clinical Trial.
We compared the incidence of proven or probable invasive fungal infections during treatment (the primary end point) between the posaconazole and fluconazole or itraconazole groups; death from any cause and time to death were secondary end points. RESULTS: A total of 304 pa …
We compared the incidence of proven or probable invasive fungal infections during treatment (the primary end point) between the posaconazole …
Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin - A prospective, randomized comparative study.
Bhatia A, Kanish B, Badyal DK, Kate P, Choudhary S. Bhatia A, et al. Indian J Pharmacol. 2019 Mar-Apr;51(2):116-119. doi: 10.4103/ijp.IJP_578_17. Indian J Pharmacol. 2019. PMID: 31142947 Free PMC article. Clinical Trial.
Therefore, this study was designed to compare the efficacy of terbinafine and itraconazole in increased dosages and duration in the treatment of tinea corporis and tinea cruris. ...CONCLUSIONS: Itraconazole and terbinafine seem to be equally effective and safe in th …
Therefore, this study was designed to compare the efficacy of terbinafine and itraconazole in increased dosages and duration in the t …
Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A systematic review and meta-analysis.
Olum R, Baluku JB, Kazibwe A, Russell L, Bongomin F. Olum R, et al. PLoS One. 2020 Oct 14;15(10):e0240374. doi: 10.1371/journal.pone.0240374. eCollection 2020. PLoS One. 2020. PMID: 33052954 Free PMC article.
Of these, 69% (n = 366) were treated with voriconazole and 31% (n = 168) with itraconazole. The median daily dose of both itraconazole and voriconazole used was 400mg. ...None of the studies compared the tolerability of itraconazole head-to-head with voricona …
Of these, 69% (n = 366) were treated with voriconazole and 31% (n = 168) with itraconazole. The median daily dose of both itracona …
Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature.
Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A. Agarwal R, et al. Mycoses. 2013 Sep;56(5):559-70. doi: 10.1111/myc.12075. Epub 2013 Mar 18. Mycoses. 2013. PMID: 23496375 Review.
A total of 31 patients (mean age, 37 years) were randomised to itraconazole (n = 17) or the control (n = 14) group. The number of patients showing overall response was significantly higher in the itraconazole group (76.5%) vs. the control (35.7%) group (P = 0.02). . …
A total of 31 patients (mean age, 37 years) were randomised to itraconazole (n = 17) or the control (n = 14) group. The number of pat …
Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial.
Liesenborghs L, Spriet I, Jochmans D, Belmans A, Gyselinck I, Teuwen LA, Ter Horst S, Dreesen E, Geukens T, Engelen MM, Landeloos E, Geldhof V, Ceunen H, Debaveye B, Vandenberk B, Van der Linden L, Jacobs S, Langendries L, Boudewijns R, Do TND, Chiu W, Wang X, Zhang X, Weynand B, Vanassche T, Devos T, Meyfroidt G, Janssens W, Vos R, Vermeersch P, Wauters J, Verbeke G, De Munter P, Kaptein SJF, Rocha-Pereira J, Delang L, Van Wijngaerden E, Neyts J, Verhamme P. Liesenborghs L, et al. EBioMedicine. 2021 Apr;66:103288. doi: 10.1016/j.ebiom.2021.103288. Epub 2021 Mar 19. EBioMedicine. 2021. PMID: 33752127 Free PMC article. Clinical Trial.
BACKGROUND: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical and clinical studies are required to investigate if itraconazole is effective for the treatment and/or prevention of COVID-19. ...In …
BACKGROUND: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical …
Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
Tachibana M, Matsuki S, Maekawa Y, Kuroda K, Shimizu T, Tsutsumi J, Ishizuka H. Tachibana M, et al. Clin Transl Sci. 2023 Nov;16(11):2153-2162. doi: 10.1111/cts.13613. Epub 2023 Sep 13. Clin Transl Sci. 2023. PMID: 37705321 Free PMC article. Clinical Trial.
Valemetostat tosylate (valemetostat) is an oral, potent, dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1 under investigation for the treatment of cancer, including non-Hodgkin's lymphomas and solid tumors. Itraconazole and fluconazole are antifungal medication …
Valemetostat tosylate (valemetostat) is an oral, potent, dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1 under investigation fo …
Itraconazole Improved Bronchial Wall Thickness in Severe Persistent Asthma: A Double-blind Placebo-controlled Randomized Clinical Trial.
Aligolighasemabadi F, Mirsadraee M, Sadeghdoust M, Ghaffari S, Sarafraz Yazdi M, Naghibi S, Hashemi Attar A. Aligolighasemabadi F, et al. Iran J Allergy Asthma Immunol. 2023 Feb 20;22(1):1-11. doi: 10.18502/ijaai.v22i1.12000. Iran J Allergy Asthma Immunol. 2023. PMID: 37002624 Free article. Clinical Trial.
Wall thickness percentage reduced significantly from 46% to 43.7% from pre- to post-treatment in the itraconazole-treated subjects. Similarly, lumen area and radius increased significantly in both the prednisolone and itraconazole groups. Itraconazole led to …
Wall thickness percentage reduced significantly from 46% to 43.7% from pre- to post-treatment in the itraconazole-treated subjects. S …
Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction.
Tapaninen T, Olkkola AM, Tornio A, Neuvonen M, Elonen E, Neuvonen PJ, Niemi M, Backman JT. Tapaninen T, et al. Clin Transl Sci. 2020 Mar;13(2):345-351. doi: 10.1111/cts.12716. Epub 2019 Nov 29. Clin Transl Sci. 2020. PMID: 31664782 Free PMC article. Clinical Trial.
The unpredictable exposure can compromise its safe and effective dosing. We examined the impact of itraconazole on ibrutinib pharmacokinetics. In a randomized crossover study, 11 healthy subjects were administered itraconazole 200 mg or placebo twice on day 1, and o …
The unpredictable exposure can compromise its safe and effective dosing. We examined the impact of itraconazole on ibrutinib pharmaco …
Itraconazole in neutropenic patients.
van't Wout JW. van't Wout JW. Chemotherapy. 1992;38 Suppl 1:23-6. doi: 10.1159/000239049. Chemotherapy. 1992. PMID: 1319311 Clinical Trial.
The median duration of treatment was 13 days with amphotericin B and 20 days with itraconazole. Nine of 16 patients responded to amphotericin B, and 10 of 16 patients responded to itraconazole. Of the patients with Aspergillus infection, 6/8 treated with itracona …
The median duration of treatment was 13 days with amphotericin B and 20 days with itraconazole. Nine of 16 patients responded to amph …
A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis.
Le T, Kinh NV, Cuc NTK, Tung NLN, Lam NT, Thuy PTT, Cuong DD, Phuc PTH, Vinh VH, Hanh DTH, Tam VV, Thanh NT, Thuy TP, Hang NT, Long HB, Nhan HT, Wertheim HFL, Merson L, Shikuma C, Day JN, Chau NVV, Farrar J, Thwaites G, Wolbers M; IVAP Investigators. Le T, et al. N Engl J Med. 2017 Jun 15;376(24):2329-2340. doi: 10.1056/NEJMoa1613306. N Engl J Med. 2017. PMID: 28614691 Free article. Clinical Trial.
Treatment with amphotericin was associated with significantly faster clinical resolution and fungal clearance and significantly lower rates of relapse and IRIS than itraconazole. The patients who received amphotericin had significantly higher rates of infusion-related reac …
Treatment with amphotericin was associated with significantly faster clinical resolution and fungal clearance and significantly lower rates …
523 results

Searches related to "itraconazole"